|Bid||3.0000 x 1400|
|Ask||3.5400 x 900|
|Day's Range||3.1500 - 3.2894|
|52 Week Range||2.1800 - 12.7900|
|Beta (5Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.80|
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will take part in two fireside chats, the first at the Piper Sandler 34th Annual Healthcare Conference, to be held November 29-December 1 in New York, and the second at the JMP Securities Hematology & Oncology Sum
Public Ventures, LLC, a wholly owned subsidiary of MDB Capital Holdings, LLC, completed its first financing as a broker-dealer for Cue Biopharma, Inc. (NASDAQ:CUE).
Cue Biopharma ( NASDAQ:CUE ) Third Quarter 2022 Results Key Financial Results Revenue: US$68.0k (down 97% from 3Q...